A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

2024-519478-38-00 Protocol NN6705-8141 Human pharmacology (Phase I) - First administration to humans Ended

Start 3 Jun 2025 · End 10 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NN6705-8141

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 116
Countries 1
Sites 1

Cardiometabolic diseases with an inflammatory component

Key facts

Sponsor
Novo Nordisk A/S
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
3 Jun 2025 → 10 Dec 2025
Decision date (initial)
2025-05-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-519478-38-00
WHO UTN
U1111-1315-6842

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Cardiometabolic diseases with an inflammatory component

VersionLevelCodeTermSystem organ class
20.0 PT 10007649 Cardiovascular disorder 100000004849

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novo Nordisk A/S

Sponsor organisation
Novo Nordisk A/S
Address
Novo Alle 1
City
Bagsvaerd
Postcode
2880
Country
Denmark

Scientific contact point

Organisation
Novo Nordisk A/S
Contact name
Novo Nordisk A/S

Public contact point

Organisation
Novo Nordisk A/S
Contact name
Novo Nordisk A/S

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 116 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-06-03 2025-06-13 2025-12-10

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-14 Netherlands Acceptable
2025-05-30
2025-05-30